Armas has kicked off 2020 with the launch of four generic injectables in the US.

While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.

As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.

NBK Capital Partners has acquired a majority stake in Polymedic, which is based in Morocco, the sixth largest pharmaceutical market in Africa that is expected to reach $2bn in 2020.

Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.